Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020:353:83-152.
doi: 10.1016/bs.ircmb.2020.02.001. Epub 2020 Mar 5.

Necroptosis, ADAM proteases and intestinal (dys)function

Affiliations
Review

Necroptosis, ADAM proteases and intestinal (dys)function

Michelle Heib et al. Int Rev Cell Mol Biol. 2020.

Abstract

Recently, an unexpected connection between necroptosis and members of the a disintegrin and metalloproteinase (ADAM) protease family has been reported. Necroptosis represents an important cell death routine which helps to protect from viral, bacterial, fungal and parasitic infections, maintains adult T cell homeostasis and contributes to the elimination of potentially defective organisms before parturition. Equally important for organismal homeostasis, ADAM proteases control cellular processes such as development and differentiation, immune responses or tissue regeneration. Notably, necroptosis as well as ADAM proteases have been implicated in the control of inflammatory responses in the intestine. In this review, we therefore provide an overview of the physiology and pathophysiology of necroptosis, ADAM proteases and intestinal (dys)function, discuss the contribution of necroptosis and ADAMs to intestinal (dys)function, and review the current knowledge on the role of ADAMs in necroptotic signaling.

Keywords: ADAM proteases; Apoptosis; Cell death; Colorectal cancer; Inflammatory bowel disease; Intestinal dysfunction; MLKL; Necroptosis; RIPK3; TNF.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest M.H and D.A. declare no competing interests. S.R.-J. has acted as a consultant and speaker for AbbVie, Chugai, Genentech Roche, Pfizer, Sanofi, Eli Lilly and Boehringer Ingelheim. He also declares that he is an inventor on patents owned by CONARIS Research Institute, which develops the sgp130Fc protein Olamkicept together with the company I-Mab. S.R.-J. has stock ownership in CONARIS.

Publication types

LinkOut - more resources